Martin A Urtasun
Overview
Explore the profile of Martin A Urtasun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Silva Machado F, Canas M, Urtasun M, Marin G, Albuquerque F, Pont L, et al.
Ther Innov Regul Sci
. 2024 Mar;
58(3):549-556.
PMID: 38436905
Background: Biosimilar medicines are defined as biological products highly similar to an already licensed biological product (RP). The market entry of biosimilars is expected to reduce the costs of biological...
2.
da Silva Machado F, Canas M, Doubova S, Urtasun M, Marin G, Osorio-de-Castro C, et al.
Regul Toxicol Pharmacol
. 2023 Sep;
144:105485.
PMID: 37659711
Biosimilars are biological medicines highly similar to a previously licensed reference product and their licensing is expected to improve access to biological therapies. This study aims to present an overview...
3.
Urtasun M, Noble M, Canas M, Bustin J, Regueiro A, Triskier F, et al.
Medicina (B Aires)
. 2022 May;
82(3):389-397.
PMID: 35639060
The clinical use of benzodiazepines (BZD) and related drugs is a controversial issue, especially prolonged prescription in older adults, which is contrary to general recommendations. Our objective was to describe...
4.
Lopes L, Salas M, Osorio-de-Castro C, Leal L, Doubova S, Canas M, et al.
Pharmacoepidemiol Drug Saf
. 2021 Dec;
31(3):343-352.
PMID: 34957616
Purpose: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for conducting DUR. However, documents that systematize...
5.
Marin G, Del Mauro J, Marin L, Urtasun M, Marin G, Nucher D, et al.
Salud Colect
. 2021 Nov;
17:e3583.
PMID: 34752020
Benzodiazepines and "Z-drugs" (BZD/Z) are overprescribed in many countries. This study evaluates their consumption in a social security sector health insurance provider with national coverage in Argentina. With a descriptive...
6.
Canas M, Marin G, Urtasun M, Leal L, Salas M, Elseviers M, et al.
Salud Colect
. 2021 Jun;
17:e3339.
PMID: 34105332
In order to compile an inventory of national data sources for drug utilization research (DUR) in Argentina and to verify publicly available data sources, we performed a cross-sectional study that...
7.
Duran C, Canas M, Urtasun M, Elseviers M, Andia T, Vander Stichele R, et al.
Rev Panam Salud Publica
. 2021 Apr;
45:e10.
PMID: 33859678
Objective: To describe the current status of regulatory reliance in Latin America and the Caribbean (LAC) by assessing the countries' regulatory frameworks to approve new medicines, and to ascertain, for...
8.
Urtasun M, Noble M, Canas M, Bustin J, Mastai R, Regueiro A
Salud Colect
. 2021 Apr;
17:e3246.
PMID: 33822541
In April 2016, the National Institute of Social Services for Retirees and Pensioners discontinued its policy of 100% coverage for 159 drugs (the "social subsidy"), including symptomatic slow-acting drugs for...
9.
Prozzi G, Canas M, Urtasun M, Buschiazzo H, Dorati C, Mordujovich-Buschiazzo P
Medicina (B Aires)
. 2018 Oct;
78(5):349-355.
PMID: 30285927
Non-steroidal anti-inflammatories (NSAIDs) are among the most commonly used drugs in clinical practice. They block cyclooxygenases (COX) enzymes, but the degree of inhibition of COX-1 and COX-2 varies between them....
10.